- Home
- R&D
R&D
OliX Pipeline
Skin Scar
• Skin scar is a result of an overgrowth of collagen in the dermis. Wound-healing frequently results in scar formation, and in extreme cases, hypertrophic scars or keloids
• Currently, no universal standard of care and no approved drugs for the reduction of scarring exist
• Scar prevention or reduction is a therapeutic area of unmet medical need
-
Hypertrophic Scar
-
Keloid Scar
Market Potential
• The global hypertrophic & keloid scar treatment market size has been projected to reach $10B by 2025. (Source: Grand View Research 2020)
Mechanism
• Target gene - Connect Tissue Growth Factor (CTGF)
Development Status
• Efficient inhibition of fibrosis identified in animal models
• Technology transferred to Hugel for Asian region (Nov. 1, 2013)
• Thesis published (preclinical trial) in Journal of Investigate Dermatology
• First in Asia to complete phase 1 clinical trial on RNAi therapeutics (May 16, 2018), Phase 2 clinical trial IND permitted in Korea (Hugel, Inc., Nov. 2018)
• Phase 2 clinical trial IND permitted in US (Oct. 2020)
• Phase 2 clinical trial in progress in Korea and US
Government Funding
Selected as Korea Drug Development Fund (KDDF) Project in 2014
for successful completion (preclinical trial)
Selected as Korea Drug Development Fund(KDDF) Project in 2018
(phase 1 in the UK and phase 2 IND in the US)
Selected as Korea Drug Development Fund(KDDF) Project in 2014 completing successgully(preclinical trial)
Selected as Korea Drug Development Fund(KDDF) Project in 2018(phase 1 in UK and phase 2 IND in US)
Publication
• Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B., Hong, S. W., & Lee, D. K. (2016). Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. Journal of Investigative Dermatology, 136(11), 2305-2313.